Our industry
BIOGERENTOLOGY: BIOLOGY OF AGING
Companies focused on aging or age-related diseases are tackling one or
more of these biological traits to find promising therapeutic candidates. In
the next sections, we’ll explore how each of these are being targeted:
Genomic instability: Genetic damage accumulation.
Telomere attrition: Shortening chromosome caps.
Epigenetic alterations: Gene expression changes.
Loss of proteostasis: Misfolded proteins.
Deregulated nutrient-sensing:
Metabolism pathways.
Mitochondrial dysfunction: Energy powerhouse failure.
Cellular senescence: Accumulation of older cells.
Stem cell exhaustion: Decline in regenerative cells.
Altered intercellular communication: Disrupted cell communication.
RECENT TRENDS
Increased Interest
The field of longevity-focused funds has gained significant attention in recent years as the aging population grows, leading to increased demand for innovative therapies.
Collaborations
Longevity-focused funds often collaborate with academic institutions, pharmaceutical companies, and research organizations to advance research and development efforts.
Diversification
Longevity funds are diversifying their portfolios to include a range of interventions, from harmaceuticals to regenerative therapies and digital health solutions.
TARGET MARKET
We offer investors exposure to cutting-edge advancements in longevity and human health technologies, driving the future of healthcare and well-being.
- Health and Wellness: US$ 4 trillion in 2020 and is projected to reach a value of US$ 6.75 trillion by 2030, expanding at a CAGR of 5.2% from 2021 to 2030. (BioSpace, 2022)Genetic Therapies: USD 18.61 billion in 2022 and is projected to reach a value of USD 93.78 billion by 2030, poised to grow at a projected CAGR of 22.41% from 2022 to 2030. (BioSpace, 2022)
- Biotechnology: USD 852.88 billion in 2020 and is projected to reach a value of USD 3.44 trillion by 2030, poised to grow at a projected CAGR of 17.83% from 2021 to 2030. (BioSpace, 2022)
- Digital Health Innovations: USD 169.36 Billion in 2022 and is projected to reach a value of USD 586.59 Billion by 2030 at a CAGR of 16.80% over the forecast period. (LinkedIn, 2023)
- Rare diseases treatment: USD 119.71 billion in 2021 and is projected to reach a value of USD 335.99 billion by 2030, growing at a CAGR of 12.15% from 2022 to 2030 (BioSpace, 2022)
- Regenerative Medicine: USD 22.24 billion in 2022 and is projected to reach a value of USD 174.72 billion by 2032 with a CAGR of 22.8% from 2023 to 2032. (Precedent Research, 2023)
Other notable fields:
Technology and AI: (predict and prevent age-related health issues), Senolytics (interventions that target senescent cells), Psychedelics (breakthrough therapies aimed at improving mental health and well-being).
